ZNF671 and pancreatic adenocarcinoma: Our results confirm that ZNF671 can be used as a biomarker, with low expression predicting worse outcomes in patients with BRCA, CESC, HNSC, KIRP, LUAD, PAAD, SARC, and UCEC.